CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells

• Main Authors: Rachel L. Mintz (Author), Yeh‐Hsing Lao (Author), Chun‐Wei Chi (Author), Siyu He (Author), Mingqiang Li (Author), Chai Hoon Quek (Author), Dan Shao (Author), Boyuan Chen (Author), Jing Han (Author), Sihong Wang (Author), Kam W. Leong (Author)
• Format: Book
• Published: Wiley, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract For patients carrying BRCA1 mutations, at least one‐third develop triple negative breast cancer (TNBC). Not only is TNBC difficult to treat due to the lack of molecular target receptors, but BRCA1 mutations (BRCA1m) also result in chemotherapeutic resistance, making disease recurrence more...